• Imaging agents

Multihance Generic Name & Formulations

General Description

Gadobenate dimeglumine 529mg/mL; soln for IV inj; preservative-free.

Pharmacological Class

Gadolinium-based contrast agent.

How Supplied

Single dose vials (5mL, 10mL, 15mL, 20mL)—5


Multihance Indications


For use in MRI of the CNS in adults and children to visualize lesions with abnormal blood brain barrier or abnormal vascularity of the brain, spine, and associated tissues. For use in magnetic resonance angiography (MRA) to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease.

Multihance Dosage and Administration

Adults and Children

MRI: Preterm neonates: not established. Give as a rapid IV bolus inj, followed by a saline flush of ≥5mL to ensure complete injection. <2yrs: 0.1–0.2mL/kg. ≥2yrs: 0.2mL/kg (0.1mmol/kg). MRA: <18yrs: not established. ≥18yrs: 0.2mL/kg (0.1mmol/kg) by rapid IV bolus inj, followed by a saline flush of ≥20mL either manually or using an automatic injector system.

Multihance Contraindications

Not Applicable

Multihance Boxed Warnings

Boxed Warning

Nephrogenic systemic fibrosis.

Multihance Warnings/Precautions


Increased risk of nephrogenic systemic fibrosis in chronic kidney disease or acute kidney injury; avoid use. Screen for renal dysfunction. Do not exceed recommended dose and allow sufficient time for drug elimination before re-administration. Have emergency resuscitative equipment available. History of asthma or other allergic disorders. Monitor for signs/symptoms of hypersensitivity reactions during and for 2hrs after administration. Increased risk of gadolinium retention with multiple lifetime doses, in pregnant patients, children, and those with inflammatory conditions; minimize repetitive imaging studies. Underlying conditions or medications that predispose to cardiac arrhythmias. Dubin Johnson syndrome. Avoid extravasation. Interpreting contrast MR images in the absence of companion non-contrast MR images. Elderly. Pregnancy. Nursing mothers.

Multihance Pharmacokinetics

See Literature

Multihance Interactions


May potentiate concomitant drugs that compete for cMOAT sites (eg, cisplatin, anthracyclines, vinca alkaloids, methotrexate, etoposide, tamoxifen, paclitaxel).

Multihance Adverse Reactions

Adverse Reactions

Nausea, headache, inj site reaction, feeling hot; hypersensitivity.

Multihance Clinical Trials

See Literature

Multihance Note

Not Applicable

Multihance Patient Counseling

See Literature